Trial
NCT06851442
Clinical Trial of Evaluating TQB3912 Tablets Combined With Fulvestrant Injection±TQB3616 Capsules for Locally Advanced or Metastatic Hormone Receptor(HR)-Positive and Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Collaborators
—
Condition
Breast Cancer
Intervention
TQB3912 tablets in combination with fulvestrant injection± TQB3616 capsules
Why stopped
This study was closed due to business reasons. Closure was not prompted by any safety or efficacy concerns.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-12-12